Masimo, the Only Patient Monitoring Company
Included, Was One of Seven Featured California Innovators
Masimo (NASDAQ: MASI) is proud to have been one of seven
California innovators featured at Pantheon 2020, the annual event
at which the California Life Sciences Association (CLSA) brings
together industry leaders in the life sciences to recognize
outstanding achievements. Held virtually this year, Pantheon 2020,
which took place last Thursday, was anchored by a series of videos
and panels highlighting stories of scientific innovation,
collaboration, and progress focused on celebrating efforts to
combat COVID-19. Masimo, the only patient monitoring company
featured, was also one of the three companies highlighted at CLSA’s
“Celebrating California Innovation” event, and at a session
dedicated to exploring how Masimo SafetyNet™ is playing a key role
in Masimo’s efforts to help clinicians and hospitals around the
world fight the pandemic.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20201207005579/en/
Masimo SafetyNet™ with Radius PPG™ and
Radius T°™ (Photo: Business Wire)
Mike Guerra, President and CEO of CLSA, commented, “Masimo is an
exemplary illustration of the resiliency and flexibility shown by
life sciences companies when California and the world were faced
with a global pandemic. The adaptability of their remote patient
monitoring technology has saved lives and allowed patients to
recover from their homes, thereby freeing up critically needed
hospital beds.”
In early 2020, harnessing its expertise in noninvasive patient
monitoring, automation, and telehealth solutions, Masimo developed
Masimo SafetyNet, a secure, home-based patient management platform
combining hospital-grade tetherless pulse oximetry, continuous
temperature measurement, and a remote data capture and surveillance
platform. Designed to help hospitals accommodate surges in COVID-19
patient volume and help lower-acuity patients recover at home and
in other alternate care spaces, Masimo SafetyNet allows clinicians
to keep an eye on their patients’ physiological status—including
oxygen saturation, respiration rate, pulse rate, and
temperature—from afar, at all times. Already in use at numerous
institutions in the U.S. and beyond, Masimo SafetyNet can be
rapidly deployed and easily scaled as needed, without additional
hardware or network infrastructure, helping caregivers provide the
best possible care as the pandemic worsens.
In his speech at Pantheon 2020, Joe Kiani, Founder and CEO of
Masimo, said, “I want to thank CLSA for highlighting our work in
helping with the global pandemic. I also want to take this time to
say we’re humbled by this, because in fact, the real heroes are the
people on the front lines using the tools we create to help
patients, especially those with COVID-19. We’ve never seen anything
like COVID-19, but as a member of CLSA, we’re proud to have used
life sciences technology, mathematics, and engineering to do the
work that we have; together we are making a difference in so many
people’s lives.”
@Masimo | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company
that develops and produces a wide array of industry-leading
monitoring technologies, including innovative measurements,
sensors, patient monitors, and automation and connectivity
solutions. Our mission is to improve patient outcomes and reduce
the cost of care. Masimo SET® Measure-through Motion and Low
Perfusion™ pulse oximetry, introduced in 1995, has been shown in
over 100 independent and objective studies to outperform other
pulse oximetry technologies.1 Masimo SET® has also been shown to
help clinicians reduce severe retinopathy of prematurity in
neonates,2 improve CCHD screening in newborns,3 and, when used for
continuous monitoring with Masimo Patient SafetyNet™ in
post-surgical wards, reduce rapid response team activations, ICU
transfers, and costs4-7 Masimo SET® is estimated to be used on more
than 200 million patients in leading hospitals and other healthcare
settings around the world,8 and is the primary pulse oximetry at 9
of the top 10 hospitals according to the 2020-21 U.S. News and
World Report Best Hospitals Honor Roll.9 Masimo continues to refine
SET® and in 2018, announced that SpO2 accuracy on RD SET® sensors
during conditions of motion has been significantly improved,
providing clinicians with even greater confidence that the SpO2
values they rely on accurately reflect a patient’s physiological
status. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry
technology, allowing noninvasive and continuous monitoring of blood
constituents that previously could only be measured invasively,
including total hemoglobin (SpHb®), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth
Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve
Index (ORi™). In 2013, Masimo introduced the Root® Patient
Monitoring and Connectivity Platform, built from the ground up to
be as flexible and expandable as possible to facilitate the
addition of other Masimo and third-party monitoring technologies;
key Masimo additions include Next Generation SedLine® Brain
Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography
with NomoLine® sampling lines. Masimo’s family of continuous and
spot-check monitoring Pulse CO-Oximeters® includes devices designed
for use in a variety of clinical and non-clinical scenarios,
including tetherless, wearable technology, such as Radius-7® and
Radius PPG™, portable devices like Rad-67™, fingertip pulse
oximeters like MightySat® Rx, and devices available for use both in
the hospital and at home, such as Rad-97®. Masimo hospital
automation and connectivity solutions are centered around the
Masimo Hospital Automation™ platform, and include Iris Gateway®,
Patient SafetyNet, Replica™, Halo ION™, UniView™, UniView: 60™, and
Masimo SafetyNet™. Additional information about Masimo and its
products may be found at www.masimo.com. Published clinical studies
on Masimo products can be found at
www.masimo.com/evidence/featured-studies/feature/.
ORi and RPVi have not received FDA 510(k) clearance and are not
available for sale in the United States. The use of the trademark
Patient SafetyNet is under license from University HealthSystem
Consortium.
References
- Published clinical studies on pulse oximetry and the benefits
of Masimo SET® can be found on our website at
http://www.masimo.com. Comparative studies include independent and
objective studies which are comprised of abstracts presented at
scientific meetings and peer-reviewed journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in
Preterm Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on
the detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
- Taenzer A et al. Impact of pulse oximetry surveillance on
rescue events and intensive care unit transfers: a before-and-after
concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth
Experience. Anesthesia Patient Safety Foundation Newsletter.
Spring-Summer 2012.
- McGrath S et al. Surveillance Monitoring Management for General
Care Units: Strategy, Design, and Implementation. The Joint
Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302.
- McGrath S et al. Inpatient Respiratory Arrest Associated With
Sedative and Analgesic Medications: Impact of Continuous Monitoring
on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14
Mar. DOI: 10.1097/PTS.0000000000000696.
- Estimate: Masimo data on file.
-
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the potential effectiveness of Masimo SafetyNet™. These
forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and
uncertainties, all of which are difficult to predict and many of
which are beyond our control and could cause our actual results to
differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to
our belief that Masimo's unique noninvasive measurement
technologies, including Masimo SafetyNet, contribute to positive
clinical outcomes and patient safety; risks related to our belief
that Masimo noninvasive medical breakthroughs provide
cost-effective solutions and unique advantages; risks related to
COVID-19; as well as other factors discussed in the "Risk Factors"
section of our most recent reports filed with the Securities and
Exchange Commission ("SEC"), which may be obtained for free at the
SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove
correct. All forward-looking statements included in this press
release are expressly qualified in their entirety by the foregoing
cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of today's date. We do not undertake any obligation to update,
amend or clarify these statements or the "Risk Factors" contained
in our most recent reports filed with the SEC, whether as a result
of new information, future events or otherwise, except as may be
required under the applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201207005579/en/
Masimo Evan Lamb 949-396-3376 elamb@masimo.com
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Apr 2023 to Apr 2024